These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 27921038)

  • 1. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
    Xue C; Zhou CC; Wu M; Mei CL
    Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Manifestation and Management of ADPKD in Western Countries.
    Sommerer C; Zeier M
    Kidney Dis (Basel); 2016 Oct; 2(3):120-127. PubMed ID: 27921039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
    Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
    Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
    Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.
    Cornec-Le Gall E; Audrézet MP; Renaudineau E; Hourmant M; Charasse C; Michez E; Frouget T; Vigneau C; Dantal J; Siohan P; Longuet H; Gatault P; Ecotière L; Bridoux F; Mandart L; Hanrotel-Saliou C; Stanescu C; Depraetre P; Gie S; Massad M; Kersalé A; Séret G; Augusto JF; Saliou P; Maestri S; Chen JM; Harris PC; Férec C; Le Meur Y
    Am J Kidney Dis; 2017 Oct; 70(4):476-485. PubMed ID: 28356211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
    Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoallelic pathogenic
    Dordoni C; Zeni L; Toso D; Mazza C; Mescia F; Cortinovis R; Econimo L; Savoldi G; Alberici F; Scolari F; Izzi C
    Clin Kidney J; 2024 Feb; 17(2):sfae026. PubMed ID: 38404363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations.
    Kim JA; Blumenfeld JD; Chhabra S; Dutruel SP; Thimmappa ND; Bobb WO; Donahue S; Rennert HE; Tan AY; Giambrone AE; Prince MR
    Radiology; 2016 Sep; 280(3):762-70. PubMed ID: 27046073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
    Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
    JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K; Trott JF; Gao G; Chapman A; Weiss RH
    BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress in autosomal dominant polycystic kidney disease].
    Hu S; Li D; Tan X; Gu J; Chen M; Zhang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1179-1187. PubMed ID: 31857514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-center analysis of genotype-phenotype characteristics of Chinese patients with autosomal dominant polycystic kidney disease by targeted exome sequencing.
    Yan Z; Wang Y; Deng W; Zhou Y; Hu Y; Qi K; Liu D; Xia R; Liu R; Zeng W; Zhang W; Xu J; Xiong F; Miao Y
    Front Genet; 2022; 13():934463. PubMed ID: 36186434
    [No Abstract]   [Full Text] [Related]  

  • 18. Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease - a case report.
    Elisakova V; Merta M; Reiterova J; Baxova A; Kotlas J; Hirschfeldova K; Obeidova L; Tesar V; Stekrova J
    BMC Nephrol; 2018 Jul; 19(1):163. PubMed ID: 29973168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.